
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is well-positioned for long-term success, with a robust pipeline of promising medications and an early approval for Lifyorli in PROC providing potential revenue growth in the near term. The recent pharmacy transition for Korlym is also expected to improve sales and patient volumes, with the potential for further upside from increased screening for hypercortisolism in larger patient populations. Overall, Corcept has shown strong financial performance and has the potential to continue delivering positive results for investors in the future.
Bears say
Corcept Therapeutics is currently facing a negative outlook due to its lack of profitability and decreasing sales projections for the future. Despite a recently increased 12-month price target of $95, the company's financial update for 1Q26 reported lower than expected revenues and a net loss per share. Additionally, there are various risks to the company's price target, including challenges in the commercial, clinical, regulatory, reimbursement, financial, legal, and intellectual property aspects of its operations.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares